Adaptive controlled noninferiority group sequential trials by Hartung, Joachim & Knapp, Guido
Adaptive Controlled Noninferiority Group Sequential Trials
Joachim Hartung1 and Guido Knapp
Department of Statistics, Dortmund University of Technology, Dortmund, Germany
Abstract: For studies comparing three independent arms: test group T , reference group
R, and control group C, we consider the hierarchical testing of the a priori ordered
hypotheses, that, in short,
(I) : T > C,
(II) : T > R−∆, ∆ > 0,
in general adaptive group sequential designs. For normally distributed response variables
with unknown variances, nested confidence intervals on the study parameters are derived
at each stage of the trial, holding a predefined confidence level. During the course of
the trial, the sample sizes can be calculated in a completely adaptive way based on
the unblinded data of previous stages. Concrete formulae for sample size updating are
provided in this paper. Moreover, in each interim analysis, it is possible to switch in the
planning from showing noninferiority of T in (II) to showing superiority of T , that is,
T > R.
A real data example is worked out in detail following an adaptive three-stage design of
Pocock (1977) type. In the example, (I) is shown in the first stage and (II) in the second
stage, so that the study stopped earlier at the second stage.
Keywords: Controlled noninferiority trials; Hierarchical testing; Group sequential con-
fidence intervals; Adaptive sample size planning; Switching from noninferiority to superi-
ority
1 Introduction
Several clinical trial guidelines, see for instance EMEA (1998), recommend to include
a placebo control group C, when an experimental test group T is to be compared to a
standard reference group R with respect to noninferiority. A more detailed regulatory
point of view is formulated by Koch (2006), who essentially says, that in areas, where
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difficulties exist with the description of the patient population in such a way that placebo-
response and response under a standard treatment can be well predicted, it may be
necessary to include both the placebo and active comparator in the confirmatory phase
III trial. It is an ethical mandate that the number of patients randomized to the placebo
comparison be limited as much as possible. An adaptive design combined with a multiple
testing procedure may offer the opportunity to stop recruitment to the placebo group after
an interim analysis, as soon as superiority of the experimental treatment over placebo has
been demonstrated. The trial is then continued into further stages to demonstrate the
noninferiority of the experimental treatment in comparison to the reference treatment.
By these considerations, we have a good description of the subject of the present
paper. With some noninferiority margin ∆ > 0, we test the a priori ordered hypotheses,
that, in short,
(I) : T > C,
(II) : T > R−∆, ∆ > 0.
When (I) is shown, we can test for (II). This proceeding has the positive consequence,
that for both hypotheses tests, we can take the same significance level, that describes the
overall test level, too. A controlled noninferiority trial is considered, for instance, also by
Pigeot et al. (2003), who present, in a one-stage trial, a different approach, where in a first
step it has to be shown that: R > C. Only when being here successful, other comparisons
are allowed. That approach bears the risk, that the whole study breaks down, when R
fails to be superior to C.
Excluding that risk, we may add in our approach at third order (III): R > C. But
the interest of the study is directed towards T , so that R is less important, especially as
R is usually well established on the market, which, however, does not imply to be very
effective.
In this paper, we consider normally distributed response variables, with unknown
variances, in general adaptive group sequential trials, see Hartung (2006). Parameterized
p-values, see Cox and Hinkley (1974), of the several stages are combined by use of the
inverse normal or Stouffer’s method, well known from meta-analysis, see Hartung, Knapp,
and Sinha (2008, Chapter 3). The resulting combined statistics are used for group se-
quential hierarchical testing of the a priori ordered hypotheses (I) and (II). A test on the
homogeneity of the stage specific treatment effects is derived. Further, the concept of re-
peated confidence intervals, see Jennison and Turnbull (2000) and references cited therein,
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is extended, in an exact way, to the case of unknown variances and possibly adaptively
chosen sample sizes. Moreover, in the considered adaptive sequential situation, where the
end of the study depends on a test decision, median unbiased maximum likelihood esti-
mators of the study parameters can be derived, including the possibly different variance
parameters.
In each interim analysis, it is possible to change the planning from showing nonin-
feriority of T to showing superiority of T with regard to R, too. We present a group
sequential confidence interval approach to switching from noninferiority to superiority,
see Bauer and Kieser (1996) and, for instance, the clinical trial guideline EMEA (2000).
Further, we develop formulae for sample size calculation in group sequential trials.
These formulae seem to be unknown so far, even in case of non-adaptive group sequential
trials, where the computed sample size for the first stage is taken in all following stages.
The outline of the present paper is as follows: In Section 2, the hierarchical testing
of the a priori ordered hypotheses is developed and the homogeneity of the stage specific
treatment differences is tested. Section 3 contains group sequential confidence intervals on
the treatment differences and the model parameters. Section 4 presents median unbiased
maximum likelihood estimators and meta-analytical estimators of the treatment effects
and of the model parameters. Section 5 contains the formulae for sample size calculation
and rules for adaptively updating the sample sizes. Section 6 presents a real data example,
following an adaptive three-stage design of Pocock (1977) type, in detail. There also, the
added test of (III): R > C is discussed in connection with the example. Section 7 contains
some further comments, especially concerning the choice of the critical values.
2 Group Sequential Testing
Let us consider a new treatment in a test group T, a standard treatment in a reference
group R, and a placebo treatment in a control group C. The associated response variables
may be denoted by XT , XR, and XC , which are mutually stochastically independent
normally distributed random variables with means µT , µR, µC and variances σ
2
T > 0,
σ2R > 0, and σ
2
C > 0, respectively, that is,
XT ∼ N
(
µT , σ
2
T
)
, XR ∼ N
(
µR, σ
2
R
)
, XC ∼ N
(
µC , σ
2
C
)
.
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At level α, 0 < α < 1/2, we first test whether T is superior to C, that ist, we test the
hypotheses:
HTC0 : µT = µC versus H
TC
1 : µT > µC . (1)
If HTCo is rejected at level α in favour of H
TC
1 , then we test, at the same level α, the
noninferiority hypotheses of T with regard to R,
HTR0 : µT = µR −∆ versus HTR1 : µT > µC −∆, ∆ ∈ [0,∆0], (2)
where ∆0 ≥ 0 denotes some margin for the noninferiority parameter ∆. This hierar-
chical testing procedure holds the overall significance level α, see Maurer, Hothorn, and
Lehmacher (1995), and, for instance, Pigeot et al. (2003) for an application of this test
principle.
We consider a comparative study, which is carried out in a number of independent
stages, say K. In the i-th stage, i = 1, . . . , K, let be X¯Ti , X¯Ri , and X¯Ci the sample
means of nTi ≥ 2, nRi ≥ 2, and nCi ≥ 2 responses in the respective treatment groups.
The variance parameters can be estimated by the corresponding sample variances S2Ti ,
S2Ri , and S
2
Ci
, which are stochastically independent of the means and follow scaled χ2-
distributions, that is, for i = 1, . . . , K,
(nTi − 1)
S2Ti
σ2T
∼ χ2nTi−1, (nRi − 1)
S2Ri
σ2R
∼ χ2nRi−1, (nCi − 1)
S2Ci
σ2C
∼ χ2nCi−1. (3)
2.1 Test Statistics
The parameters of interest are θTC = µT − µC and θTR = µT − µR. Denote tν the central
t-distribution with ν degrees of freedom, then with the true parameters θTC and θTR, we
have, in good approximation, at the i-th stage, i = 1, . . . , K,
DTCi (θTC) :=
X¯Ti − X¯Ci − θTC√
σˆ2Ti/nTi + σˆ
2
Ci
/nCi
∼ tνi(TC), (4)
DTRi (θTR) :=
X¯Ti − X¯Ri − θTR√
σˆ2Ti/nTi + σˆ
2
Ri
/nRi
∼ tνi(TR), (5)
where
σˆ2Ti = S
2
Ti
, σˆ2Ci = S
2
Ci
, σˆ2Ri = S
2
Ri
,
and with Satterthwaite’s approximation,
νi(TC) =
(
S2Ti/nTi + S
2
Ci
/nCi
)2(
S2Ti/nTi
)2
/(nTi − 1) +
(
S2Ci/nCi
)2
/(nCi − 1)
,
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νi(TR) =
(
S2Ti/nTi + S
2
Ri
/nRi
)2(
S2Ti/nTi
)2
/(nTi − 1) +
(
S2Ri/nRi
)2
/(nRi − 1)
.
Provided σ2T = σ
2
C , then both parameters are estimated in the i-th stage by the pooled
estimator
σˆ2Ti = σˆ
2
Ci
=
(nTi − 1)S2Ti + (nCi − 1)S2Ci
nTi − nCi − 2
, (6)
and in (4), we get an exact t-distribution with νi(TC) = nTi +nCi−2 degrees of freedom,
i = 1, . . . , K. Analogously, we proceed when σ2T = σ
2
R.
If σ2T = σ
2
C = σ
2
R =: σ
2, then the common variance is estimated in the i-th stage by
σˆ2i =
(nTi − 1)S2Ti + (nCi − 1)S2Ci + (nRi − 1)S2Ri
nTi + nCi + nRi − 3
(7)
and in (4) and (5), νi(TC) = νi(TR) = nTi + nCi + nRi − 3, i = 1, . . . , K.
Let Ftν denote the cumulative distribution function of a t-variate with ν degrees of
freedom, then it holds, for the parameterized 1− p-values,
1− pdi (θd) = Ftνi (d)(Ddi (θd)) ∼ U(0, 1), d = TC, TR, i = 1, . . . , K, (8)
where U(0, 1) stands for the uniform distribution in the unit interval. Consequently, we
obtain
zdi (θd) := Φ
−1(1− pdi (θd)) ∼ N (0, 1), d = TC, TR, i = 1, . . . , K, (9)
with Φ−1 the inverse of the standard normal cumulative distribution function Φ.
The stages of the trial are assumed to be independent. So up to the j-th stage, we
define the combining pivotal statistics
Zdj (θd) :=
j∑
i=1
zdi (θd) ∼
√
j N (0, 1), d = TC, TR, j = 1, . . . , K. (10)
Let Y1, . . . YK , in general, be mutually independent N (0, 1)-distributed random vari-
ables. Then, for predefined level α, 0 < α < 1/2, positive critical values cv1(d), . . . , cvK(d)
may be defined by the following probability condition:
P
(
j∑
i=1
Yi ≤ cvj(d) for all j = 1, . . . , K
)
= 1− α, d = TC, TR, (11)
see Hartung (2006), and a respective comment in Section 7.
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Using these critical values cvj(d), we get the following probability statements for the
combining pivotal statistics from (10),
Pθd
(
Zdj (θd) ≤ cvj(d) for j = 1, . . . , k ≤ K
)≥ 1− α for k < K,= 1− α for k = K,
d = TC, TR.
(12)
Consequently, we can formulate the following test procedure at overall level of at most
α as implied by (12): At the k-th stage, k = 1, . . . , K, we reject HTC0 in favour of H
TC
1 ,
see (1),
if ∃i0 ∈ {1, . . . , k} : ZTCi0 (0) > cvi(TC). (13)
Provided the decision is made for the alternative HTC1 , then in the noninferiority test
problem (2), we decide in favour of the alternative HTR1,∆, ∆ ∈ [0,∆0],
if ∃j∆ ∈ {1, . . . , k} : ZTRj∆ (−∆) > cvj(TR). (14)
Provided the placebo arm C is not stopped after stage i0, since each stage of the trial
should be controlled by a placebo group C, for instance, because of safety concerns of the
treatments, we can continue the three-armed trial even in the case of an early stage i0
yielding significance in (13) without the risk of losing the already shown significance.
If we are satisfied with showing T as being noninferior to R, we will stop the trial after
that stage j∗, when ZTRj∗ (−∆o) > cvj∗(TR) the first time and j∗ ≥ i0.
In case unexpected, for T favourable estimates of the involved parameters in the groups
T and R have been observed up to stage j∗ < K, this may lead to considerations to switch
from showing noninferiority to showing superiority of T with respect to R. The trial is
then continued by further planning with ∆ = 0 for the testing problem (2). Note that by
(14), there is no risk to lose the noninferiority once shown.
2.2 Homogeneity of the Treatment Differences
Let us consider the extended model that each stage has individual parameters, say µd,i
and σ2d,i > 0, d = T,R,C, i = 1, . . . , K. Then
θTC,i = µT,i − µC,i and θTR,i = µT,i − µR,i, i = 1, . . . , K, (15)
are the stage specific parameters for the treatment differences. The distributions of the
test statistics DTCi (θTC,i), see (4), and D
TR
i (θTR,i), see (5), remain valid, so that, see (9),
zdi (θd,i) ∼ N (0, 1), d = TC, TR, i = 1, . . . , K. (16)
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So as in (10), we get
Z˜dj (θd,1, . . . , θd,j) :=
j∑
i=1
zdi (θd,i) ∼
√
j N (0, 1), d = TC, TR, j = 1, . . . , K, (17)
and we can apply (11) with the positive critical values cvj(d) to give the following prob-
ability statement, see (12),
Pθd,1,...,θd,k
(
−cvj(d) ≤ Z˜dj (θd,1, . . . , θd,j) ≤ cvj(d) for j = 1, . . . , k ≤ K
)
≥ 1− 2α, d = TC, TR.
(18)
For example, with d = TC, the stage specific estimators θˆTC,i = X¯Ti− X¯Ci , i = 1, . . . , j ≤
k ≤ K, satisfy the inequalities in the brackets of (18) because of zTCi (θˆTC,i) = 0.
When we assume that the parameters θd,i are really identical up to the k-th stage, say
θd,i = θd for i = 1, . . . , k, then Z˜
d
j (θd,1, . . . , θd,j) = Z
d
j (θd) from (10), j = 1, . . . , k, and by
(18), there holds
Pθd(−cvj(d) ≤ Zdj (θd) ≤ cvj(d) for j = 1, . . . , k ≤ K) ≥ 1− 2α,
d = TC, TR.
(19)
If now for a common level α, we cannot find some value for θd satisfying the inequalities in
(19), we can conclude with an error rate of at most 2α, that the assumption of identical
parameters up to the k-th stage was wrong. This can formally be stated as a test on
homogeneity of the treatment differences.
In testing, for d = TC or TR,
Hd0,hom(k) : θd,1 = . . . = θd,k versus H
d
1,hom(k) : θd,i1 6= θd,i2 (20)
for some i1, i2 ∈ {1, . . . , k}, k = 2, . . . , K, the homogeneity hypothesis Hd0,hom(k) will be
rejected at level of at most 2α, if
C˜I
d
k := {y ∈ IR | −cvj(d) ≤ Zdj (y) ≤ cvj(d) for j = 1, . . . , k} = ∅. (21)
If Hd0,hom(k
∗) is rejected, then also Hd0,hom(k) will be rejected for k
∗ ≤ k ≤ K. An
alternative to this homogeneity test does not seem to be known. A possible way to verify
(21) numerically will be provided in Section 3.2.
A specific group sequential homogeneity test was claimed, for instance, by Koch (2006),
who also pointed out its need for regulatory concerns.
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Suppose that up to stage k − 1 the sets C˜Idj , j = 1, . . . , k − 1, are nonempty and C˜Ik
is empty for a common level α. Thus, up to an error rate of 2α, see (20), we may consider
that the parameters of the underlying treatment difference are no longer homogeneous in
all the stages. So, with regard to statistical concerns, results from this stage k should
not influence conclusions, or non-conclusions, from the previous stages. Nevertheless, one
may try to find an explanation for the revealed treatment behavior.
The basic test principle applied here to (20) is the same as used by Hartung and
Knapp (2003) in deriving a test on homogeneity of variances of random treatment-by-
sample interactions. As usually done, the significance level in the homogeneity test may
be chosen higher than in the efficiency test. In the extreme case, when α comes near 1/2
in (19), all stage specific estimates of the treatment differences had to be nearly equal in
order to avoid a rejection of the homogeneity hypothesis H0,hom in (20), at level near 1.
Additionally to (20), in an approximate way, homogeneity tests from meta-analysis
may be applied, see Hartung, Knapp, and Sinha (2008, Chapter 6).
3 Group Sequential Confidence Intervals
The functions Ftν (·) and Φ−1(·), used in (8) and (9), are (strictly) monotone increas-
ing in their arguments. The pivotal test statistics DTCi (θTC) and D
TR
i (θTR) from (4)
and (5) are monotone decreasing in θTC and θTR, respectively, implying that z
d
i (θd) =
Φ−1(Ftνi(d)(D
d
i (θd))), see (9), is monotone decreasing in θd, d = TC, TR, i = 1, . . . , k.
Consequently, we can state for the whole functions from (10):
ZTCj (θTC) and Z
TR
j (θTR) are monotone decreasing in θTC and θTR,
respectively, j = 1, . . . , K.
(22)
3.1 One-sided Confidence Intervals
From (21), we derive the lower confidence sets on θd as
CIdk,I(θd) :={y ∈ IR | Zdj (y) ≤ cvj(d) for j = 1, . . . , k},
d = TC, TR, k = 1, . . . , K,
(23)
and again by (12), the confidence coefficient of CIdK,I is at least 1− α and exactly 1− α
for k = K. Further, the confidence sets are nested,
CIdk+1,I(θd) ⊂ CIdk,I(θd), k = 1, . . . , K − 1, d = TC, TR, (24)
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Using now that Zdj (y) is monotone decreasing in y, see (22), we obtain that the confidence
sets are genuine intervals, allowing the following representation:
CIdk,I(θd) =
[
Ldk,∞
)
, d = TC or TR, (25)
where Ldk = max{Ld(1), . . . , Ld(k)} and Ld(j) solves
Zdj (L
d(j)) = cvj(d), j = 1, . . . , k, k = 1, . . . , K. (26)
Note that the solutions Ld(j) in (26) are unique and can be iteratively found, for instance,
by use of the bisection method. Let us apply the group sequential confidence intervals to
our hierarchical testing problem at overall significance level α, 0 < α < 1/2. Since the
intervals are nested, see (24), we obtain in accordance with (13) and (14) by use of Ldk
from (25) the following decision rules:
At stage k, k = 1, . . . , K,
(i) if 0 ≥ LTCk , then stay with HTC0 in (1)
and HTR0,∆0 in (2),
(ii) if 0 < LTCk and −∆0 ≥ LTRk , then decide for HTC1 in (1)
and stay with HTR0,∆0 in (2),
(iii) if 0 < LTCk and −∆ < LTRk , then decide for HTC1 in (1)
and for HTR1,∆ in (2), ∆ ∈ [0,∆0].
(27)
In case (iii), we may stop the trial after stage k. If at some stage j∗ < K we observe
−∆0 < LTRj∗ , we may consider, when continuing the study, to switch in the further planning
to show T as superior to R.
In case (ii), if k < K, we may stop the control arm C and continue the trial only with
the arms T and R.
In case (i), we have to continue the trial provided k < K.
3.2 Two-sided Confidence Intervals
In analogy to (23), let us define the upper confidence sets on θd as
CIdk,II(θd) :={y ∈ IR | −cvj(d) ≤ Zdj (y) for j = 1, . . . , k},
d = TC, TR, k = 1, . . . , K,
(28)
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and by (12), each confidence set has a confidence coefficient of at least 1−α, being exactly
1− α for k = K. The interval representation, using (22), is given by
CIdk,II(θd) =
(−∞, Udk ] , d = TC or TR, (29)
where Udk = min{Ud(1), . . . , Ud(k)} and Ud(j) solves uniquely
Zdj (U
d(j)) = −cvj(d), j = 1, . . . , k, k = 1, . . . , K. (30)
The two-sided confidence interval on θd at stage k is defined as the intersection of the two
corresponding one-sided confidence intervals,
CIdk (θd) :=
[
Ldk, U
d
k
]
, d = TC or TR, (31)
where Ldk is from (25) and U
d
k is from (29), k = 1, . . . , K. The confidence intervals are
nested,
CIdk+1(θd) ⊂ CIdk (θd), k = 1, . . . , K − 1, d = TC, TR, (32)
and each confidence interval has a confidence coefficient of at least 1− 2α, 0 < α < 1/2.
Denote Idk (θd) = [L
d(j), Ud(j)], see (26) and (30), the individual two-sided confidence
interval on θd at the k-stage. Then it holds,
CId1 (θd) = I
d
1 (θd) and
CIdk (θd) = CI
d
k−1(θd) ∩ Idk (θd), k = 2, . . . , K, d = TC, TR,
(33)
Since CIdk ⊂ Idk , the interval Idk is another two-sided confidence interval with confidence
coefficient of at least 1− 2α. The interval Idk results from the boundaries in stage k alone
and will be always nonempty. Therefore, Idk may be preferred to CI
d
k , see for instance
Jennison and Turnbull (2000, p. 192) in their corresponding setting. Depending on the
choice of α, the two-sided confidence interval CIdk (θd) from (31) may be empty.
Let us look at the homogeneity test (20). We have to check whether the set C˜I
d
k
defined in (21) is empty. Now we can state that this set coincides with the two-sided
confidence interval: C˜I
d
k = CI
d
k (θd). Hence, if CI
d
k (θd) is empty, that is U
d
k < L
d
k, see (31),
we have to reject the homogeneity hypothesis Hd0,hom(k) in (20) with an error rate of at
most 2α. Consequently, preferring Idk to CI
d
k does not provide some real advantage.
On the other hand, under the model assumptions of identical parameters underlying
the different stages of the study, the probability to obtain an empty confidence interval
CIdk (θd) is bounded by 2α, d = TC or TR.
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3.3 Approximative Confidence Intervals
Instead of the implicitly defined confidence intervals, we provide approximative confidence
intervals in an explicit form. Their boundaries may be used also as starting points in an
iterative procedure to determine the exact confidence intervals.
Let us approximate the central t-distributions involved in the combining statistics by
normal distributions with the same first two moments. The variance of a tν-variate is
ν/(ν − 2). So we may define the following weights at the i-th stage, i = 1, . . . , K,
wTCi :=
√
νi(TC)− 2
νi(TC)[σˆ2Ti/nTi + σˆ
2
Ci
/nCi ]
, (34)
provided νi(TC) > 2, see (4), and thus, the statistic z
TC
i (θTC) from (9) is approximated
by
zTCi (θTC)appr = Φ
−1 (Φ [wTCi (X¯Ti − X¯Ci − θTC)]) , (35)
which is approximately N (0, 1)-distributed. Hence, the combining statistic ZTCj (θTC)
from (10) is approximated by
ZTCj (θTC)appr =
j∑
i=1
wTCi (X¯Ti − X¯Ci − θTC), j = 1, . . . , K, (36)
which is approximately N (0, j)-distributed. Equating ZTCj (y)appr to cvj(TC), see (26),
and to −cvj(TC), see (30), and solving for y yields the following approximate individual
confidence interval on θTC , see (33), for j = 1, . . . , K,
ITCj (θTC)appr =
j∑
i=1
wTCi (X¯Ti − X¯Ci)∑j
h=1w
TC
h
± cvj(TC)∑j
h=1w
TC
h
. (37)
By setting
CITC1 appr = I
TC
1 (θTC)appr and
CITCk (θTC)appr = CI
TC
k−1(θTC)appr ∩ ITCk (θTC)appr, k = 2, . . . , K,
(38)
we obtain approximations of the confidence intervals CITCk on θTC = µT − µC in (31).
Proceeding analogously, we get approximate confidence intervals on θTR = µT − µR.
3.4 Confidence Intervals on the Means
Let, based on the data of the i-th stage, i = 1, . . . , K, σˆ2i (T ) be an unbiased estimator of
σ2T , which is stochastically independent of X¯Ti and satisfies, see (3), (6) or (7),
νi(T ) σˆ
2
i (T )/σ
2
T ∼ χ2νi(T ), (39)
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then with the i-th test statistic
DTi (µT ) :=
√
nTi
X¯Ti − µT√
σˆ2i (T )
∼ tνi(T ), i = 1, . . . K, (40)
we derive the combining statistics, see (10), for j = 1, . . . , K,
ZTj (µT ) :=
j∑
i=1
Φ−1
(
Ftνi(T )
(
DTi (µT )
)) ∼√j N (0, 1). (41)
In the same way as above, see (31), we obtain the two-sided confidence interval on µT at
the k-th stage, k = 1, . . . , K, as
CITk (µT ) =
[
max
1≤j≤k
LT (j), min
1≤j≤k
UT (j)
]
, (42)
where with positive critical values cvj(T ) in (11), L
T (j) and UT (j) are the unique solutions
of
ZTj (L
T (j)) = cvj(T ) and Z
T
j (U
T (j)) = −cvj(T ), j = 1, . . . , k ≤ K. (43)
The confidence intervals are nested and possess confidence coefficients of at least 1 −
2α, 0 < α < 1/2.
Defining the weights, for i = 1, . . . , K,
wTi :=
√
(νi(T )− 2)nTi
νi(T )σˆ2i (T )
, νi(T ) > 2, (44)
we receive the approximate individual confidence interval on µT at the j-th stage, see
(37), for i = 1, . . . , K,
ITj (µT )appr :=
j∑
i=1
wTi X¯Ti∑j
h=1 w
T
h
± cvj(T )∑j
h=1w
T
h
, (45)
Again by CIT1 (µT )appr = I
T
1 (µT )appr and CI
T
k (µT )appr = CI
T
k−1(µT )appr ∩ ITk (µT )appr, k =
2, . . . , K, we obtain approximations of CITk (µT ) in (42). Confidence intervals on µC and
µR are derived in the same way.
3.5 Confidence Intervals on the Variance Parameters
Let Fχ2ν denote the cumulative distribution function of a χ
2-variate with ν degrees of
freedom. Using the pivotal χ2-statistics from (39), which are monotone decreasing in
σ2T > 0, we obtain, in analogy to (8),
Fχ2
νi(T )
(
νi(T )
σˆ2i (T )
σ2T
)
∼ U(0, 1), i = 1, . . . , K, (46)
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leading as in (10) to the pivotal combining statistics, for j = 1, . . . , K,
V Tj (σ
2
T ) :=
j∑
i=1
Φ−1
[
Fχ2
νi(T )
(
νi(T )
σˆ2i (T )
σ2T
)]
∼
√
j N (0, 1), (47)
which are monotone decreasing in σ2T > 0. Denote cv
∗
1, . . . , cv
∗
K positive critical values
defined by (11).
Let σ2T,L(j) and σ
2
T,U(j) be the unique solutions of the equations
V Tj (σ
2
T,L(j)) = cv
∗
j and V
T
j (σ
2
T,U(j)) = −cv∗j , j = 1, . . . , k ≤ K, (48)
then in analogy to (31), we derive the confidence intervals on σ2T as
V CITk (σ
2
T ) =
[
max
1≤j≤k
σ2T,L(j), min
1≤j≤k
σ2T,U(j)
]
, k = 1, . . . , K, (49)
which are nested and possess confidence coefficients of at least 1− 2α, 0 < α < 1/2. For
common α, an empty interval indicates that the assumption of homogeneous variances
over the stages may be violated, see (20) and Section 3.2.
Applying the rule of error propagation, we derive for the χ2-statistics of (39), that the
transformations
gTi (σ
2
T ) :=
√
2
νi(T ) σˆ2i (T )
σ2T
−
√
2 νi(T ), i = 1, . . . , K, (50)
are approximately N (0, 1)-distributed, so that GTj (σ2T ) :=
∑j
i=1 g
T
i (σ
2
T ) is approximately
N (0, j)-distributed, j = 1, . . . , K. Solving now GTj (y) ≤ cv∗j and GTj (y) ≥ −cv∗j for y > 0
yields the approximate individual confidence intervals, see (33), on σ2T as
V ITj (σ
2
T )appr := [aT (j)
2, b∗T (j)
2], j = 1, . . . , K, (51)
where
b∗T (j)
2 =
{
bT (j)
2 if bT (j) > 0,
∞ if bT (j) ≤ 0,
aT (j) =
∑j
i=1
√
2 νi(T ) σˆi(T )∑j
h=1
√
2 νh(T ) + cv∗j
and
bT (j) =
∑j
i=1
√
2 νi(T ) σˆi(T )∑j
h=1
√
2 νh(T )− cv∗j
.
Again by setting V CIT1 (σ
2
T )appr = V I
T
1 (σ
2
T )appr and V CI
T
k (σ
2
T )appr = V CI
T
k−1(σ
2
T )appr ∩
V ITk (σ
2
T )appr, k = 2, . . . , K, we get explicit approximations to the confidence intervals on
σ2T in (49). In the same way, we may derive confidence intervals on σ
2
C and σ
2
R.
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4 Group Sequential Point Estimation
4.1 Estimation of the Treatment Difference
For θTC = µT − µC , the combining statistic ZTCj (θTC) from (10) is N (0, j)-distributed
with mode and median 0. The maximum likelihood (ML) estimator θˆ
(1)
TC(j) of θTC at stage
j is given by
θˆ
(1)
TC(j) solves Z
TC
j
(
θˆ
(1)
TC(j)
)
= 0, j = 1, . . . , K. (52)
The solution in (52) is unique.
The global p-value at stage j is
pTC(j) = 1− Φ
(
ZTCj (θTC)/
√
j
)
, j = 1, . . . , K, (53)
and solving (53) for θTC such that pTC(j) = 1/2 yields θˆ
(1)
TC(j) as solution. Since Z
TC
j (θ)
is monotone in θTC , we can conclude:
θˆ
(1)
TC(j) is median unbiased, j = 1, . . . , K, (54)
see Cox and Hinkley (1974, p. 273), that is, the ML-estimator θˆ
(1)
TC(j) lies with equal
probability as well below the parameter θTC as above θTC .
Equating the approximative combining statistic ZTCj (θTC)appr from (36) to 0 and
solving for θTC yields the midpoint of the approximative individual confidence interval
ITCj (θTC)appr from (37) as approximate median unbiased ML-estimator θˆ
(2)
TC(j) of θTC at
the j-th stage, given by
θˆ
(2)
TC(j) =
j∑
i=1
wTCi (X¯Ti − X¯Ci)∑j
h=1 w
TC
h
, j = 1, . . . , K, (55)
where the weights are defined in (34). Note that, in combining the mean differences of
the stages, their inverse estimated standard errors are used in the weights and not their
inverse estimated variances as known from the ’minimum variance unbiased’ estimator
of the overall mean difference in meta-analysis, see Hartung, Knapp, and Sinha (2008,
Chapter 8). Weighted mean differences like θˆ
(2)
TC(j) from (55) are used in the generalized
Cochran-Wald statistics considered by Hartung, Bo¨ckenhoff, and Knapp (2003).
Replacing in (55) the weights wTCi by
w˜TCi =
(
σˆ2Ti
nTi
+
σˆ2Ci
nCi
)−1
, i = 1, . . . , K, (56)
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we obtain the meta-analytical estimator θˆ
(3)
TC(j) of θTC up to the j-th stage, j = 1, . . . , K.
For θTR = µT − µR, the estimators θˆ(h)TR(j) of θTR at stage j, h = 1, 2, 3, are defined
analogously.
4.2 Estimation of the Mean and Variance Parameters
With the combining statistic from (41), the unique solution of ZTj
(
µˆ
(1)
T (j)
)
= 0 defines
the median unbiased ML-estimator µˆ
(1)
T (j) of µT at the j-th stage, j = 1, . . . , K, see
above. The midpoint of the interval ITj (µT )appr in (45) is the approximate median unbiased
ML-estimator µˆ
(2)
T (j) of µT at the j-th stage, and the replacing there the weight w
T
i by
w˜Ti = nTi/σˆ
2
i (T ) yields the midpoints as the meta-analytical estimator µˆ
(3)
T (j) of µT at
the j-th stage, j = 1, . . . , K.
By a quite analogous argumentation as above in Section 4.1, we derive with the com-
bining statistic from (47) the median unbiased ML-estimator σ̂2T
(1)
(j) of σ2T at the j-th
stage as follows:
σ̂2T
(1)
(j) solves uniquely V Tj
(
σ̂2T
(1)
(j)
)
= 0, j = 1, . . . , K. (57)
The solution of GTj (y) = 0, see (50), (51), is the approximate median unbiased ML-
estimator of σ2T at the j-th stage, which can be represented as:
σ̂2T
(2)
(j) =
(
j∑
i=1
√
νi(T ) σˆi(T )∑j
h=1
√
νh(T )
)2
, j = 1, . . . , K. (58)
Since the variance of σˆ2i (T ) from (39) is 2σ
4
T/νi(T ), the meta-analytical inverse variance
weighted estimator of σ2T up to the j-th stage takes on the following form:
σ̂2T
(3)
(j) =
j∑
i=1
νi(T ) σˆ
2
i (T )∑j
h=1 νh(T )
, j = 1, . . . , K, (59)
which may also be considered at the pooled estimator of σ2T up to the j-th stage. Note
that in (58) the estimated standard deviations are combined, and in (59), the estimated
variances. In the groups R and C, the parameters are estimated in an analogous way.
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5 Sample Size Calculation and Adaptive Updating
Suppressing the subscript i and supposing known variances, let us consider the test statis-
tic, see (5),
DTR0 (θTR) =
X¯T − X¯R − θTR√
σ2T/nT + σ
2
R/nR
∼ N (0, 1), (60)
which should be used for testing, with fixed ∆ ∈ [0,∆0] and fixed value θ∗TR > −∆, the
point hypotheses
H∗0 : θTR = −∆ versus H∗1 : θTR = θ∗TR > −∆, (61)
so that under H∗0, D
TR
0 (−∆) ∼ N (0, 1).
Then for given level α, 0 < α < 1, and desired power 1 − βTR, 0 < βTR < 1, the
required sample sizes nT and nR should satisfy the following inequality,
θ∗TR − (−∆)√
σ2T/nT + σ
2
R/nR
≥ Φ−1(1− α) + Φ−1(1− βTR). (62)
For ease of presentation, we will use this formula (62) as a good approximation also in
the following, when t-statistics will be applied. Denote stage 0 a priori information and
external restrictions.
Then after stage j, based on previous information of stages 0, 1, . . . , j, let θˆTR(j) >
−∆, θˆTC(j) > 0, σˆ2T (j) , σˆ2R(j), and σˆ2C(j), j = 0, 1, . . . , K, be reasonable estimates of their
corresponding parameters, for instance, by use of the point estimators provided in Section
4. Assume the test above is placed after stage j, and put θ∗TR = θˆTR(j), σ
2
T = σ̂
2
T (j), and
σ2R = σ̂
2
R(j), then formula (62) becomes the following inequality, with θˆTR(j) + ∆ > 0,
θˆTR(j) + ∆√
σ̂2T (j)/nT + σ̂
2
R(j)/nR
≥ Φ−1(1− α) + Φ−1(1− βTR), j = 0, . . . , K. (63)
Whereas 1 − βTR is the desired power at θTR(j) = θˆTR(j) > −∆ in the testing problem
(2) after stage j, let the desired power at θTC = θˆTC(j) > 0 in the testing problem (1)
after stage j be 1−βTC , 0 < βTC < 1. So, with the same level α and by use of DTC0 (θTC),
see (60), we derive analogously for the required sample sizes nT and nC in the testing
problem (1) after stage j the following inequality, with θˆTC(j) > 0,
θ̂TC(j)√
σ̂2T (j)/nT + σ̂
2
C(j)/nC
≥ Φ−1(1− α) + Φ−1(1− βTC), j = 0, . . . , K. (64)
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For an easy use of these formulae in the following, let us define sets of feasible sample
sizes, for k = 0, . . . , K,
ΓTR(κ, βTR,∆)k := {(nT , nR) ∈ IN × IN |nT and nR satisfy (63) for j = k and α = κ}(65)
ΓTC(κ, βTC)k := {(nT , nC) ∈ IN × IN |nT and nC satisfy (64) for j = k and α = κ} . (66)
Recall now from (11), for d = TC or TR, the event
A :=
{
h∑
i=1
Yi ≤ cνh(d) for all h = 1, . . . , K
}
,
and let us consider for an arbitrary, but fixed, stage j, j ∈ {1, . . . , K}, the event
B :=
{
h∑
i=1
Yi ≤ cνh for h = 1, . . . , j − 1, and
j−1∑
i=1
Yi +
K∑
i=j
Yi ≤ cνK(d)
}
.
Clearly, the probability of event B is larger than of event A. Moreover,
∑K
i=j Yi isN (0, K−
(j − 1))-distributed and may be collapsed to √K − (j − 1)Yj, which has the same distri-
bution. Hence, we obtain{
h∑
i=1
Yi ≤ cνh(d) for h = 1, . . . , j − 1, and
j−1∑
i=1
Yi +
√
K − (j − 1)Yj ≤ cνK(d)
}
⊃
{
h∑
i=1
Yi ≤ cνh(d) for all h = 1, . . . , K
}
. (67)
Further, denote θ0d a value for θd under the null-hypothesis H
d
0, given as H
TC
0 from (1)
for d = TC or as HTR0,∆ from (2) for d = TR and ∆ ∈ [0,∆0] fixed. The aim is, that
at some stage j, by use of the combining pivotal statistic from (10), we will obtain:
Zdj (θ
0
d) > cνj(d).
The following proceeding is a consequence of (67). If we decide after stage j−1 to omit
the interim analyses j up to K − 1, we can assign the remaining weight √K − (j − 1)
to the next final study part, named stage (j,K), and build the final test statistic, see (9)
and (10),
Zd(j,K)(θ
0
d) = Z
d
j−1(θ
0
d) +
√
K − (j − 1) Φ−1 [1− pd(j,K)(θ0d)] , (68)
where Zd(j,K)(θ
0
d) ∼
√
K N (0, 1) under Hd0, j = 1, . . . , K, defining Zd0 = 0. The test
statistic Zd(j,K)(θ
0
d) has to be compared with the K-th critical value cνK(d) in testing H
d
0.
We want to reach cνK(d) by use of Z
d
(j,K)(θ
0
d), that is, we have to equate:
cνK(d) = Z
d
j−1(θ
0
d) +
√
K − (j − 1) Φ−1 [1− pd(j,K)(θ0d)] , (69)
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and solving the equation for the unknown p-value yields as solution the projected p-value
pˆd(j,K)(θ
0
d) = 1− Φ
[
cνK(d)− Zdj−1(θ0d)√
K − (j − 1)
]
, d = TC or TR, j = 1, . . . , K. (70)
Now cνK(d) will be reached with probability 1 − βd when the stage specific t-tests, con-
cerning d = TC or TR, which are planned for the next final stage (j,K), will pro-
vide levels attained or p-values below the projected p-values with probability 1 − βTC
and 1 − βTR, respectively. Observed p-values below the projected p-values would yield:
Zd(j,K)(θ
0
d) > cνK(d), d = TC or TR. Thus, the significance or α-level of these tests, say
αd(j,K), d = TC, TR, are chosen to satisfy
αd(j,K) = pˆ
d
(j,K)(θ
0
d), d = TC, TR, j = 1, . . . , K. (71)
Consequently, conditioned on θTC = θˆTC(j − 1) > 0 and θTR = θˆTR(j − 1) > −∆, when
the above mentioned t-tests would be applied, the required sample sizes MTj , MCj and
MRj of the respective groups in the final stage (j,K), for holding the power 1− βTC for
d = TC in (1) and the power 1− βTR for d = TR in (2), should be feasible and satisfy:
(MTj ,MCj) ∈ ΓTC(pˆTC(j,K)(0), βTC)j−1 and (72)
(MTj ,MRj) ∈ ΓTR(pˆTR(j,K)(−∆), βTR,∆)j−1, (73)
see (65), (66), (70), (71). Thus, the projected p-values can be named as conditional error
functions.
If we do not want to finish the trial in this way and have in mind the originally planned
K − (j − 1) further stages, we will not perform the above mentioned t-tests in the final
stage (j,K) but in stage j. Consequently, we will choose now the sample size in each
group for stage j proportionally as, see (72) and (73),
nTj ≈
MTj
K − j + 1 , nCj ≈
MCj
K − j + 1 , nRj ≈
MRj
K − j + 1 , j = 1, . . . , K, (74)
which is a (slightly) conservative choice by (67). Note that each sample size should be at
least 2 in each stage. Then we use cνj(TC) as critical value for Z
TC
j (0) and cνj(TR) as
critical value for ZTRj (−∆), ∆ ∈ [0,∆0), in stage j, see (10).
Especially for j = 1:
nT1 ≈
MT1
K
, nC1 ≈
MC1
K
, and nR1 ≈
MR1
K
(75)
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where, see (65) and (66),
(MT1 ,MC1) ∈ ΓTC(αTC , βTC)0, αTC := 1− Φ(cνK(TC)/
√
K),
(MT1 ,MR1) ∈ ΓTR(αTR, βTR,∆)0, αTR := 1− Φ(cνK(TR)/
√
K),
are feasible starting sample sizes.
By taking the initial sample sizes in all stages, (75) provides formulae for sample size
calculation in non-adaptive group sequential trials.
Further, formulae (72) to (75) provide an optimal allocation of sample sizes at each
stage, when minimizing, for instance, the total sample size at each stage under some side
conditions. Often in practice, a chosen randomization scheme of the treatments has to be
taken into account.
We start with the above calculated initial sample sizes in the first stage of the study.
Then with the proceeding above, we reach the full power 1− βTC , conditioned on θTC =
θˆTC(K − 1) > 0 and 1 − βTR, conditioned on θTR = θˆTR(K − 1) > −∆, latest in stage
j = K, if not stopped before because of shown significance.
The total power, say 1 − βTotal, of the hierarchical testing of (1) and (2), can be
estimated by
1− βTC − βTR ≤ 1− βTotal ≤ min{1− βTC , 1− βTR}. (76)
When we replace the combining statistic Zj by its approximation Zj,appr from (36) in
the above considerations, we obtain an approximative proceeding, that fulfills the purpose
of sample size calculation in practical situations.
Further, we may formally define the p-values, see (8), as suiting to the null-hypothesis
that θd is the true parameter, see Cox and Hinkley (1974, p. 221). So, we may apply
the general result that under the null-hypothesis p-values preserve their distribution and
independence (for continuous null-distributions) when sample sizes are chosen adaptively
in a consecutive way, see for instance Brannath, Posch, and Bauer (2002). All the above
procedures are based on such p-values. Consequently, all the statements remain valid
when sample sizes are chosen adaptively as demonstrated in this section, see also Hartung
(2006).
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Table 1: Controlled noninferiority clinical trial concerning patients with asthma bronchiale
in an adaptive 3-stage Pocock (1977) design with early stop for shown significance after
stage 2 at given one-sided significance level α = 0.025.
Adaptive Critical
Stage sample size Data [in `] Test value value
i nTi nRi nCi x¯Ti x¯Ri x¯Ci σˆi Z
TC
i (0) Z
TR
i (−0.2) ZTRi (0) cνi
0 — 2.6 2.5 2.1 0.9 — ∆0 = 0.2 —
1 116 58 29 2.65 2.56 2.13 0.87 2.86 2.06 0.45 2.289
2 96 48 24 2.69 2.51 2.15 0.81 5.76 4.70 1.71 3.237
3 STOP Because of shown significance
6 A Real Data Example
Let us consider a clinical trial one of the authors was concerned with as a statistical
advisor. Two different inhalers, a new test drug T and a standard reference drug R, for
treating patients with asthma bronchiale are compared with respect to a lung function
parameter named FEV1: forced expiratory volume in 1 second, measured in liter (`). A
control group C received a placebo drug, but the same basic treatment as the groups T
and R. Methods of the previous sections will be demonstrated for the hierarchical testing
problem (1) and (2) in the present application, where ∆0 = 0.2` is a usual margin of
the noninferiority parameter for the considered clinical variable. To increase the number
of observations on the new drug, the three drugs were randomized in blocks of size 7
containing each: 4×T, 2×R, 1×C. By technical reasons, the randomization scheme could
not be changed in an interim analysis. Further, a common variance σ2 could be assumed
in all groups so that formulae (7) is used for its estimation and computing the degrees of
freedom at each stage.
The one-sided significance level is chosen as α = 0.025, the power in showing T as
superior to C should be 1−βTC = 0.95, and 1−βTR = 0.90 should be the power for showing
T as a noninferior to R, which means by (76) for the total power 1−βTotal of the hierarchical
testing: 0.85 ≤ 1−βTotal ≤ 0.90. The study design was chosen as an adaptive three-stage
design of Pocock (1977) type for both comparisons (1) and (2). Using the combining
statistic from (10), we obtain in (11) the critical values cνj = 2.289
√
j, j = 1, 2, 3, see
Hartung (2006, p. 533), or Jennsion and Turnbull (2000, p. 26) for the two-sided level
0.05.
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Using the prior guesses of the parameters at stage 0 from Table 1, the differences
θTR = µT − µR and θTC = µT − µC are initially estimated by θˆTR(0) = 0.10` and
θˆTC(0) = 0.50`, and σ by σˆ(0) = 0.90`. Since the sample sizes have to satisfy nT = 2nR
and nT = 4nC , we get, by use of (75) from (72) and (73) the following conditions for MT1 :
MT1 ≥ (1 + 4)(2.289 + 1.645)2(0.9/0.5)2 = 250.7, and
MT1 ≥ (1 + 2)(2.289 + 1.282)2(0.9/[0.1 + 0.2])2 = 344.3.
Using (75), we compute a minimum of 29 blocks of size 7 for the first stage, such that
nT1 = 116, nR1 = 58, nC1 = 29.
The trial started with these numbers of patients. In the first stage we observed, see
Table 1, x¯T1 − x¯C1 = 0.52, x¯T1 − x¯R1 = 0.09, and σˆ1 = 0.87, associated with ν1 = 203− 3
degrees of freedom, see (7).
For the testing problem (1), we compute, see (10), ZTC1 (0) = 2.86 > 2.289 = cν1, such
that by (13), the null-hypothesis HTC0 can be rejected already after the first stage. For the
testing problem (2), with ∆ = ∆0 = 0.2, we compute Z
TR
1 (−0.2) = 2.06. In the further
planning, we can look only on the testing in (2). By (70), we obtain the projected p-value
pˆTR(2,3)(−0.2) = 1− Φ
[
2.289
√
3− 2.06√
2
]
= 1− Φ[1.3468].
Using the estimates of the first stage, that is, θˆTR(1) = 0.09 and σˆ
2
T (1) = σˆ
2
R(1) = 0.87
2,
see (63), we obtain by (73),
MT2 ≥ (1 + 2)(1.3468 + 1.282)2(0.87/[0.9 + 0.2])2 = 186.6.
Using (74), we compute a minimum of 24 blocks of size 7 for the second stage, implying
the sample sizes nT2 = 96, nR2 = 48 and nC2 = 24.
In stage 2, we observed the estimates, see Table 1, x¯T2− x¯R2 = 0.18, x¯T2− x¯C2 = 0.54,
and σˆ2 = 0.81, associated with ν2 = 168− 3 degrees of freedom, see (7). We compute for
the testing problem (2), ZTR2 (−0.2) = 2.06 + 2.64 = 4.70 > 2.289
√
2 = 3.237 = cν2 such
that the noninferiority of T with regard to R is shown, too. Consequently, the study is
stopped after stage 2. The observed treatment effects seemed to be not favourable (or too
expensive) for an attempt to reach superiority also in (2) at the third stage. Note that in
the second stage, too, the test for (1) exceeds the critical value, ZTC2 (0) = 2.86 + 2.90 =
5.76 > 3.237.
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In the hierarchical testing problem, we could add as a third step to test at level α,
too:
HRC0 : µR = µC versus H
RC
1 : µR > µC (77)
provided both null-hypotheses HTC0 in (1) and H
TR
0,∆0
in (2) are rejected at level α each. But
then the sample sizes of both groups T and R should be equal in each stage. Otherwise,
the comparisons will become unfair, that is, in the present constellation, T has a greater
chance than R to be significantly superior to C.
The combining test statistic from (10), applied to the testing problem (77) above, takes
on the value ZRC2 (0) = 2.16 + 1.77 = 3.93 > 3.237, such that in a third step, H
RC
0 could
have been rejected at the second stage, too. Otherwise, the study had to be continued,
provided we had included (77) in advance.
But in the present study, the interest is directed mainly towards the new drug T. The
reference drug R is already on the market and had shown its superiority, when compared
to placebo groups earlier in large studies. So also for safety concerns about the treatment,
the number of observations on the new drug was chosen larger than on the reference drug.
Since the treatment difference between T and C was expected to be larger than between
T and R−∆0, the control group C was chosen smaller than the reference group R but in
a minimum relation to the test group T . So external considerations were more important
than an optimal allocation of the sample sizes according to the formulae (72) to (75).
In the further analysis of the present example, the treatment effects are illustrated by
the confidence intervals from (31). We obtain in the realized two stages of the study the
following (≥ 0.95)-confidence intervals on the treatment difference µT − µC ,
CI1(µT − µC) = [0.10, 0.94] and CI2(µT − µC) = [0.23, 0.83]
and (≥ 0.95)-confidence intervals on the treatment difference µT − µR as
CI1(µt − µR) = [−0.23, 0.41] and CI2(µT − µR) = [−0.10, 0.36].
The simultaneous confidence level is at least 90% by Bonferroni’s inequality.
Confidence intervals on the single parameters are provided by Section 3.5. We con-
fine ourselves to the common variance parameter σ2. Using the same critical values as
above and the data from Table 1, we obtain (≥ 0.95)-confidence intervals on σ2 by the
approximation (51) as:
V I1(σ
2)appr = [0.781
2, 1.0182] and V I2(σ
2)appr = [0.771
2, 0.9392],
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that is,
V CI2(σ
2)appr = V I1(σ
2)appr ∩ V I2(σ2)appr = [0.7812, 0.9392],
and using (47), by equating
V1(σ
2) = Φ−1
[
Fχ2200
(
200
0.872
σ2
)]
= ±2.289 and
V2(σ
2) = V1(σ
2) + Φ−1
[
Fχ2165
(
165
0.812
σ2
)]
= ±3.237,
and solving for σ2, we compute the exact (≥ 0.95)-confidence intervals on σ2 as
V I1(σ
2) = [0.7802, 0.9822] and V I2(σ
2) = [0.7762, 0.9202],
so that
V CI2(σ
2) = V I1(σ
2) ∩ V I2(σ2) = [0.7802, 0.9202].
In the same way, let us consider only the parameter σ2 for point estimation discussed in
Section 4. The approximate median unbiased ML-estimates implied by (58) are
σ̂2
(2)
(1) = 0.872 and σ̂2
(2)
(2) = 0.84662
and by (59), we get the meta-analytical estimates
σ̂2
(3)
(1) = 0.872 and σ̂2
(3)
(2) = 0.84342.
The exact median unbiased ML-estimates, see (57), are obtained by equating V1(σ
2) =
0 and V2(σ
2) = 0 and solving for σ2 as:
σ̂2
(1)
(1) = 0.87152 and σ̂1
(1)
(2) = 0.84282.
It should be noted, that by the early stopping of the study, we passed up the chance
to improve the point and interval estimates in the third stage.
Further, we would like to remark, that the placebo arm C was not dropped after
the first stage for several reasons. For example, the homogeneity, see (20), and eventual
unwanted adverse side effects should be controlled in the following stages by a placebo
group, too. Ethical and legal problems could be excluded.
Finally, it might be noted, that in the present study we had reliable a priori informa-
tion, which, however, could be recognized earliest in the first interim analysis. So, when
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we had conducted a non-adaptive group sequential trial by taking in the second stage
the same sample sizes as computed by our formulae for the initial stage, we would had
observed nearly surely quite similar results. Hence, the benefit of the adaptive design is
here just having saved the costs for observing the difference of 35 patients.
But with non-reliable a priori information, the consequences might become quite dif-
ferent, see, for instance Hartung (2006), who points out ethical aspects and possible legal
complications with non-adaptive designs, when, for instance, the treatment concerns a
severe disease where patients cannot get back their status from baseline.
7 Final Remarks
In Section 5, we have computed sample sizes n using a normal approximation for applying
t-variates. Nearly exact values are achieved by correcting the sample size n with the
variance of a tn−1-variate, that is, replacing n by ncorr = n(n − 1)/(n − 3), n ≥ 4. The
idea behind the correction is the same as in replacing a t-variate by a normal variate with
identical variance. However, computed values have usually to be modified to fit some side
conditions.
In Section 2.1 we have defined positive one-sided critical values cνj, j = 1, . . . , K, by
the probability condition (11). For a fixed number of stages K and an overall significance
level α, we get an O’Brien and Fleming (1979) design with constant critical values in (11),
say cvj = consOBF (K,α), and a Pocock (1977) design with monotone increasing critical
values given as cvj =
√
j consPO(K,α), j = 1, . . . , K, see Hartung (2006), where also
some of these one-sided critical values are tabulated. Designs with intermediate values of
the critical values are considered, for instance, in Jennison and Turnbull (2000).
Usually, two-sided critical values at level 2α for the corresponding symmetric two-
sided tests are tabulated in literature. For K ≥ 2, these two-sided critical values are
slightly smaller than the one-sided critical values at level α. At least for α ≤ 0.05, these
two-sided critical values may be used here for practical applications, see Jennison and
Turnbull (2000, p. 192).
We have defined the two-sided confidence interval CIk, see (31), as the intersection of
the one-sided intervals CIk,I and CIk,II , see (25) and (28), and the confidence coefficient
of CIk is at least 1− 2α. If we use the critical values of the correspondent two-sided tests
at level 2α, we get a two-sided confidence interval, say CI0k , that is slightly narrower than
CIk for K ≥ 2, but has a confidence coefficient of at least 1− 2α as well. Moreover, the
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final CI0K reaches a confidence coefficient of exactly 1− 2α.
However, using the lower boundary of CI0k in the test decisions (27), the test level α
cannot be guaranteed. Indeed, no severe differences are expected for practical applications
at least for α ≤ 0.05, see above.
Moreover, let us consider the testing situation in a group sequential trial. In a superior-
ity test, for example, the null-hypothesis is rejected at level α, if we observe Zk∗(0) > cνk∗
in at least one stage k∗ ∈ {1, . . . , K}, see (12). Usually the study is stopped after stage
k∗ because of having shown significance, see, for instance, Jennison and Turnbull (2000),
Hartung (2006). Such a stop is a correct decision, since the study result cannot be re-
versed later in the same study. Consequently, when we continue the study, we have no
risk to lose the already shown significance.
Suppose k∗ < K and the study is continued to reach a larger data base, for instance,
for safety reasons in clinical trials, then we may observe Zk(0) ≤ cνk in all further stages
k > k∗ without contradicting the already shown superiority. This fact is able to induce
misunderstandings in practical applications caused by a lack of knowledge on the theoreti-
cal background. The same problem may arise, when, after shown significant noninferiority,
the trial is continued for an attempt to reach superiority. Such possible misunderstand-
ings are avoided by using CIk, that means, its lower boundary, and the testing procedure
(27). The automatically implied homogeneity test (20) by computing CIk would react
when quite different results would have been observed in later stages.
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